sorbitol has been researched along with glucagon-like peptide 2 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gunji, E; Io, F; Kato, K; Kimura, K; Koretsune, H; Okumura-Kitajima, L; Sugisaki-Kitano, M; Uchida, S; Yamamoto, K | 1 |
1 other study(ies) available for sorbitol and glucagon-like peptide 2
| Article | Year |
|---|---|
SGL5213, a novel and potent intestinal SGLT1 inhibitor, suppresses intestinal glucose absorption and enhances plasma GLP-1 and GLP-2 secretion in rats.
Topics: Animals; Diabetes Mellitus, Experimental; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucose; Intestinal Absorption; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sorbitol | 2019 |